Table 5 Multivariable analysis of key outcomes

From: Goat lung surfactant for treatment of respiratory distress syndrome among preterm neonates: a multi-site randomized non-inferiority trial

Outcome

GLSE

n = 52

n (%)

Beractant

n = 46

n (%)

Unadjusted odds ratio (95% CI), p value

Adjusted odds ratioa (95% CI), p-value

Death

21 (40.4%)

14 (30.4%)

1.5 (0.7–3.6) p = 0.306

1.13 (0.40–3.29) p = 0.815

Repeat dose (one or more)

34 (65.4%)

8 (17.4%)

9.0 (3.5–23.3) p < 0.001

9.8 (3.2 –30.1) p < 0.001

Need for mechanical ventilation at 24 h after surfactant

32/49 (65.3%)

15/46 (32.6%)

3.89 (1.66–9.12) p = 0.002

5.1 (1.5 –17.2) p = 0.009

Average FiO2 required in first 48 h after surfactant administration (%)

50.5 ± 21.2

33.3 ± 14.5

Difference in means 17.2 (9.8–24.6) p < 0.001

Difference in means 12.5 (5.5–19.6) p < 0.001

  1. FiO2-fractional inspired oxygen concentration
  2. aAdjusted for study center and baseline characteristics that were substantially different (10%) between group A and group B: sex of baby, rupture of membranes for more than 18 h, antepartum hemorrhage, required positive pressure ventilation immediately after birth, receipt of delivery room CPAP, and InSurE (intubation, surfactant administration and extubation)
Back to article page